Personalis, Inc.
PSNL · Services-Medical Laboratories · 104.7M shares · +20%/yr ↑ dilution · EDGAR filings ↗
Reference price $13.15 · est. market cap ~$1.4B — last insider sale, 2026-06-26 (estimated from the dated SEC Form 4 price × shares outstanding — not a live quote)
Grade
D44Genomics/MRD-diagnostics company with deep losses and cash burn, funded.
Strengths
- Strong liquidity — current ratio 6.8 (73rd)
Risks
- Deep losses — operating margin -126%, ROE -31%
- Cash burn — FCF -$79M
- Reimbursement/customer-concentration risk — per 10-K
Notable findings
- No interest coverageInterest coverage -429.55 (cannot cover interest)
- Net lossNet loss (net margin -116.7%)
- Cash burnNegative free cash flow (-79.5M)
- Exec changeRecent 8-K item 5.02 8-K ↗
- Fund exitedNotable fund(s) exited this quarter: VANGUARD GROUP INC
- Chronic dilutionShare count +20%/yr over 3y (dilution, book value/share -31%)
- Strong balance sheetStrong balance sheet — $240M cash & investments, ~12 quarters of runway
- Notable holderHeld by 6 notable fund(s): ARK Investment Management LLC, STATE STREET CORP, GOLDMAN SACHS GROUP INC +3 more (as of 2026-03-31)
- Insider sellingInsider selling — 7 open-market sale(s) by 2 insider(s) (cluster of 2 insiders, ~$4M, last 6mo) Form 4 ↗
- Revenue declineRevenue -10.8% YoY
Quarterly revenue
Last 4 quarters · from SEC filings.
Key metrics
Gross margin
22.7%
Operating margin
-126.4%
Net margin
-116.7%
Return on equity
-31.1%
Return on assets
-24.3%
Revenue growth (QoQ)
-10.8%
Interest coverage
-429.5×
Current ratio
6.8×
Free cash flow
-$79M
EBITDA
-$78M
Tangible book value
$261M
Cash & investments
$240M
Cash runway
12q
Stock comp / revenue
13.5%
Insider transactions · last 18 months
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| 2026-06-26 | Hall Christopher M | Option exercise | 100K | $1.61 |
| 2026-06-26 | Tachibana Aaron | Sell | 51K | $13.18 |
| 2026-06-26 | Tachibana Aaron | Option exercise | 22K | $5.32 |
| 2026-06-26 | Tachibana Aaron | Option exercise | 29K | $9.16 |
| 2026-06-26 | Hall Christopher M | Sell | 100K | $13.15 |
| 2026-06-04 | Tachibana Aaron | Option exercise | 40K | $9.16 |
| 2026-06-04 | Tachibana Aaron | Sell | 40K | $12.01 |
| 2026-05-29 | Hall Christopher M | Sell | 80K | $11.02 |
| 2026-05-29 | Tachibana Aaron | Option exercise | 39K | $9.16 |
| 2026-05-29 | Tachibana Aaron | Sell | 39K | $11.58 |
| 2026-05-29 | Hall Christopher M | Option exercise | 80K | $1.61 |
| 2026-05-28 | Hall Christopher M | Sell | 20K | $11.02 |
| 2026-05-28 | Hall Christopher M | Option exercise | 20K | $1.61 |
| 2026-05-12 | WIDDER KENNETH J | Grant | 6.2K | — |
| 2026-05-12 | BOWMAN A BLAINE | Grant | 6.2K | — |
| 2026-05-12 | EASTHAM KARIN | Grant | 6.2K | — |
| 2026-05-12 | MYERS WOODROW A JR | Grant | 6.2K | — |
| 2026-05-12 | Shoff Lonnie | Grant | 6.2K | — |
| 2026-05-12 | Bloom Olivia Kyusuk | Grant | 6.2K | — |
| 2026-05-12 | EASTHAM KARIN | Grant | 6.2K | — |
| 2026-03-15 | Moore Stephen Michael | Grant | 28K | — |
| 2026-03-15 | Chen Richard | Grant | 47K | — |
| 2026-03-15 | Hall Christopher M | Grant | 88K | — |
| 2026-03-15 | Tachibana Aaron | Grant | 34K | — |
| 2026-01-22 | Tachibana Aaron | Sell | 1.2K | $11.50 |
| 2026-01-22 | Tachibana Aaron | Option exercise | 1.2K | $9.16 |
| 2025-12-22 | Tempus AI, Inc. | Buy | 28K | $8.93 |
| 2025-12-19 | Tempus AI, Inc. | Buy | 30K | $8.39 |
| 2025-12-18 | Tempus AI, Inc. | Buy | 31K | $7.91 |
| 2025-12-17 | Tempus AI, Inc. | Buy | 32K | $7.86 |
| 2025-11-25 | Tempus AI, Inc. | Buy | 9.7K | $10.08 |
| 2025-11-25 | Tachibana Aaron | Sell | 104K | $10.78 |
| 2025-11-25 | Tachibana Aaron | Option exercise | 104K | $9.16 |
| 2025-11-25 | Tempus AI, Inc. | Buy | 14K | $11.00 |
| 2025-11-24 | Tempus AI, Inc. | Buy | 25K | $9.87 |
| 2025-11-21 | Tempus AI, Inc. | Buy | 9.9K | $8.84 |
| 2025-11-21 | Tempus AI, Inc. | Buy | 17K | $9.74 |
| 2025-11-20 | Tempus AI, Inc. | Buy | 29K | $8.63 |
| 2025-11-19 | Tempus AI, Inc. | Buy | 31K | $8.12 |
| 2025-11-18 | Tempus AI, Inc. | Buy | 65K | $7.67 |
| 2025-11-03 | Hall Christopher M | Sell | 30K | $8.99 |
| 2025-07-28 | Tachibana Aaron | Sell | 641 | $6.57 |
| 2025-07-28 | Chen Richard | Sell | 452 | $6.57 |
| 2025-05-16 | Chen Richard | Sell | 910 | $4.95 |
| 2025-05-16 | Tachibana Aaron | Sell | 1.3K | $4.95 |
| 2025-05-16 | Moore Stephen Michael | Sell | 1.7K | $4.95 |
| 2025-01-28 | Tachibana Aaron | Sell | 708 | $5.79 |
| 2025-01-28 | Chen Richard | Sell | 519 | $5.79 |
All non-derivative Form 4 activity (SEC), newest first.
Clinical trials
| Trial | Title | Phase | Status | Primary completion |
|---|---|---|---|---|
| NCT06230185 ↗ | CtDNA Based MRD Testing for NAC Monitoring in TNBC TNBC - Triple-Negative Breast Cancer, Minimal Residual Disease | — | Recruiting | 2025-08-30 |
Source: ClinicalTrials.gov (U.S. NIH) · active studies first.
Notable events (8-K)
Recent filings
| Form | Filed | Period | Accession |
|---|---|---|---|
| 8-K | 2026-05-20 | 2026-05-19 | 0001193125-26-232533 ↗ |
| 8-K | 2026-05-13 | 2026-05-12 | 0001193125-26-221846 ↗ |
| 8-K | 2026-05-13 | 2026-05-12 | 0001193125-26-221574 ↗ |
| 10-Q | 2026-05-07 | 2026-03-31 | 0001193125-26-211896 ↗ |
| 8-K | 2026-05-07 | 2026-05-07 | 0001193125-26-211850 ↗ |
| 8-K | 2026-03-17 | 2026-03-13 | 0001193125-26-110852 ↗ |
| 10-K | 2026-02-26 | 2025-12-31 | 0001193125-26-076615 ↗ |
| 8-K | 2026-02-26 | 2026-02-26 | 0001193125-26-076553 ↗ |
| 8-K | 2026-01-08 | 2026-01-08 | 0001193125-26-007037 ↗ |
| 8-K | 2025-11-28 | 2025-11-28 | 0001193125-25-302644 ↗ |
| 8-K | 2025-11-25 | 2025-11-24 | 0001193125-25-294454 ↗ |
| 8-K | 2025-11-10 | 2025-11-07 | 0001193125-25-273416 ↗ |